Today: September 1, 2015, 5:59 am

INCYTE - JAKAFI’s Label Expansion in Ref. Metastatic Pancreatic Cancer = Multi-Billion Potential! - new market research report published
INCYTE - JAKAFI’s Label Expansion in Ref. Metastatic Pancreatic Cancer = Multi-Billion Potential! - a new market research report on 2014-04-17 04:36:03
Positive interim Overall Survival analysis data from the PhII, RECAP trial of Ruxolitinib (L – JAKAFI for MF, oral JAK 1/2 inhibitor, PhII/III in PV/ET, partnered with Novartis for Ex-US rights) in combination with capecitabine in recurrent or treatment-refractory metastatic pancreatic cancer pts is a pleasant surprise.

The hazard ratio for overall survival in the intent-to-treat (ITT) population was 0.79, and in a pre-specified subgroup analysis (pts identified prospectively as most likely to benefit from JAK pathway inhibition, 50% of the enrolled population), the HR for OS was 0.47 (one-sided p=0.005). With an ´Orphan drug´ status for this indication and no approved drug for metastatic pancreatic cancer, label expansion could make… For more details, please read our report released o 21st Aug., 2013 on INCY, titled "JAKAFI´s Label Expansion in Ref. Metastatic Pancreatic Cancer = Multi-Billion Potential!"

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Press Information

Published by
Mike King
London: +44 (0) 203 086 8600
Related Articles

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.